XL092 Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: Zanzalintinib

Filter by location:

Boston, Massachusetts1 trial

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Dana Farber/Harvard Cancer Center

Phase 1

St Louis, Missouri1 trial

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Washington University School of Medicine

Phase 2

Salt Lake City, Utah1 trial

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Huntsman Cancer Institute at University of Utah

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.